Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Partner and localizer of BRCA2 (PALB2) is a breast cancer susceptibility gene that plays an important role in DNA repair. This is the first study assessing the prevalence of PALB2 mutations in early-onset and familial breast/ovarian cancer patients from Pakistan. Materials and Methods PALB2 mutation screening was performed in 370 Pakistani patients with early-onset and familial breast/ovarian cancer, who were negative for BRCA1, BRCA2, TP53, CHEK2, and RAD51C mutations, using denaturing high-performance liquid chromatography analysis. Mutations were confirmed by DNA sequencing. Novel PALB2 alterations were analyzed for their potential effect on protein function or splicing using various in silico prediction tools. Three-hundred and seventy-two healthy controls were screened for the presence of the identified (potentially) functional mutations. Results A novel nonsense mutation, p.Y743*, was identified in one familial breast cancer patient (1/127, 0.8%). Besides, four in silico-predicted potentially functional mutations including three missense mutations and one 5' untranslated region mutation were identified: p.D498Y, novel p.G644R, novel p.E744K, and novel c.-134_-133delTCinsGGGT. The mutations p.Y743* and p.D498Y were identified in two familial patients diagnosed with unilateral or synchronous bilateral breast cancer at the ages of 29 and 39, respectively. The other mutations were identified in an early-onset (! 30 years of age) breast cancer patient each. All five mutations were absent in 372 healthy controls suggesting that they are disease associated. Conclusion Our findings show that PALB2 mutations account for a small proportion of early-onset and hereditary breast/ovarian cancer cases in Pakistan.
Abstract
Purpose Partner and localizer of BRCA2 (PALB2) is a breast cancer susceptibility gene that plays an important role in DNA repair. This is the first study assessing the prevalence of PALB2 mutations in early-onset and familial breast/ovarian cancer patients from Pakistan. Materials and Methods PALB2 mutation screening was performed in 370 Pakistani patients with early-onset and familial breast/ovarian cancer, who were negative for BRCA1, BRCA2, TP53, CHEK2, and RAD51C mutations, using denaturing high-performance liquid chromatography analysis. Mutations were confirmed by DNA sequencing. Novel PALB2 alterations were analyzed for their potential effect on protein function or splicing using various in silico prediction tools. Three-hundred and seventy-two healthy controls were screened for the presence of the identified (potentially) functional mutations. Results A novel nonsense mutation, p.Y743*, was identified in one familial breast cancer patient (1/127, 0.8%). Besides, four in silico-predicted potentially functional mutations including three missense mutations and one 5' untranslated region mutation were identified: p.D498Y, novel p.G644R, novel p.E744K, and novel c.-134_-133delTCinsGGGT. The mutations p.Y743* and p.D498Y were identified in two familial patients diagnosed with unilateral or synchronous bilateral breast cancer at the ages of 29 and 39, respectively. The other mutations were identified in an early-onset (! 30 years of age) breast cancer patient each. All five mutations were absent in 372 healthy controls suggesting that they are disease associated. Conclusion Our findings show that PALB2 mutations account for a small proportion of early-onset and hereditary breast/ovarian cancer cases in Pakistan.
참고문헌 (53)
- Xia B, "Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2", Mol Cell, 22, pp.719~729 (2006)
- Howlett NG, "Biallelic inactivation of BRCA2 in Fanconi anemia", Science, 297, pp.606~609 (2002)
- Rahman N, "PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene", Nat Genet, 39, pp.165~167 (2007)
- Antoniou AC, "Breast-cancer risk in families with mutations in PALB2", N Engl J Med, 371, pp.497~506 (2014)
- Erkko H, "A recurrent mutation in PALB2 in Finnish cancer families", Nature, 446, pp.316~319 (2007)
- Casadei S, "Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer", Cancer Res, 71, pp.2222~2229 (2011)
- Damiola F, "Mutation analysis of PALB2 gene in French breast cancer families", Breast Cancer Res Treat, 154, pp.463~471 (2015)
- Janatova M, "The PALB2 gene is a strong candidate for clinical testing in BRCA1-and BRCA2-negative hereditary breast cancer", Cancer Epidemiol Biomarkers Prev, 22, pp.2323~2332 (2013)
- Teo ZL, "Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families", Breast Cancer Res, 15, pp.R17~ (2013)
- Guenard F, "Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2in non-BRCA1", 2 French Canadian families with high risk of breast cancer, 2010, pp.14, 515~526
- Ding YC, "Germline mutations in PALB2 in African-American breast cancer cases", Breast Cancer Res Treat, 126, pp.227~230 (2011)
- Leyton Y, "Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population", BMC Cancer, 15, pp.30~ (2015)
- Cao AY, "The prevalence of PALB2 germline mutations in BRCA1", BRCA2negative Chinese women with early onset breast cancer or affected relatives, 2009, pp.114, 457~462
- Kim H, "Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer", Breast Cancer Res Treat, 161, pp.95~102 (2017)
- Phuah SY, "Prevalence of PALB2 mutations in breast cancer patients in multi-ethnic Asian population in Malaysia and Singapore", PLoS One, 8, pp.e73638~ (2013)
- Nakagomi H, "Analysis of PALB2 mutations in 155 Japanese patients with breast and", or ovarian cancer, 2016, pp.21, 270~275
- Rashid MU, "Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients", Int J Cancer, 119, pp.2832~2839 (2006)
- Rashid MU, "Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients", Fam Cancer, 11, pp.307~311 (2012)
- Rashid MU, "Constitutional CHEK2 mutations are infrequent in early-onset and familial breast", ovarian cancer patients from Pakistan, 2013, pp.13, 312~
- Rashid MU, "Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan", Breast Cancer Res Treat, 145, pp.775~784 (2014)
- Rashid MU, "High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients", BMC Cancer, 16, pp.673~ (2016)
- Rashid MU, "Association between the BsmI polymorphism in the vitamin D receptor gene and breast cancer risk: results from a Pakistani case-control study", PLoS One, 10, pp.e0141562~ (2015)
- Underhill PA, "Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography", Genome Res, 7, pp.996~1005 (1997)
- Dansonka-Mieszkowska A, "A novel germline PALB2deletion in Polish breast and ovarian cancer patients", BMC Med Genet, 11, pp.20~ (2010)
- Garcia MJ, "Analysis of FANCB and FANCN", PALB2 fanconi anemia genes in BRCA1, Breast Cancer Res Treat, pp.2009, 113[DOI]
- Ernst C, "Performance of in silico prediction tools for the classification of rare BRCA1", 2 missense variants in clinical diagnostics, 2018, pp.11, 35~
- Thompson ER, "Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls", Breast Cancer Res, 17, pp.111~ (2015)
- Siraj AK, "Expanding the spectrum of germline variants in cancer", Hum Genet, 136, pp.1431~1444 (2017)
- Singh J, "Screening of over 1000 Indian patients with breast and", or ovarian cancer with a multi-gene panel : prevalence of BRCA1, Breast Cancer Res Treat, pp.2018, 170[DOI]
- Jian W, "Clinical and genetic characterization of hereditary breast cancer in a Chinese population", Hered Cancer Clin Pract, 15, pp.19~ (2017)
- Park JS, "Variants of cancer susceptibility genes in Korean BRCA1", 2 mutationnegative patients with high risk for hereditary breast cancer, 2018, pp.18, 83~
- Blanco A, "Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer", Breast Cancer Res Treat, 132, pp.307~315 (2012)
- Aloraifi F, "Detection of novel germline mutations for breast cancer in non-BRCA1", 2 families, 2015, pp.282, 3424~3437
- Bogdanova N, "PALB2 mutations in German and Russian patients with bilateral breast cancer", Breast Cancer Res Treat, 126, pp.545~550 (2011)
- Catucci I, "PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo", Genet Med, 16, pp.688~694 (2014)
- Hartley T, "Mutation analysis of PALB2 in BRCA1and BRCA2-negative breast and", or ovarian cancer families from Eastern Ontario, Canada, 2014, pp.12, 19~
- Kluska A, "PALB2 mutations in BRCA1", 2-mutation negative breast and ovarian cancer patients from Poland, 2017, pp.10, 14~
- Tedaldi G, "Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer", Oncotarget, 8, pp.47064~47075 (2017)
- Sy SM, "MRG15 is a novel PALB2-interacting factor involved in homologous recombination", J Biol Chem, 284, pp.21127~21131 (2009)
- Karchin R, "Next generation tools for the annotation of human SNPs", Brief Bioinform, 10, pp.35~52 (2009)
- Chan PA, "Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR)", Hum Mutat, 28, pp.683~693 (2007)
- Cecener G, "Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey", Mol Biol Rep, 43, pp.1273~1284 (2016)
- Kuusisto KM, "Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1", 2founder mutation-negative breast and, Breast Cancer Res, pp.2011, 13[DOI]
- Adank MA, "PALB2 analysis in BRCA2-like families", Breast Cancer Res Treat, 127, pp.357~362 (2011)
- Silvestri V, "PALB2 mutations in male breast cancer : a populationbased study in Central Italy", Breast Cancer Res Treat, 122, pp.299~301 (2010)
- Sauty de Chalon A, "Are PALB2 mutations associated with increased risk of male breast cancer?", Breast Cancer Res Treat, 121, pp.253~255 (2010)
- Silvestri V, "Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene", Cancer, 123, pp.210~218 (2017)
- Heikkinen T, "The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype", Clin Cancer Res, 15, pp.3214~3222 (2009)
- Tischkowitz M, "PALB2", FANCN : recombining cancer and Fanconi anemia, 2010, pp.70, 7353~7359
- Couch FJ, "Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer", J Clin Oncol, 33, pp.304~311 (2015)
- Kraus C, "Gene panel sequencing in familial breast", ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1, Int J Cancer, pp.2017, 140[DOI]
- Wong-Brown MW, "Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer", Int J Cancer, 134, pp.301~305 (2014)
- Schoolmeester JK, "Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and", or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2, 2017, pp.70, 1426~